The latest biotech news

News and Trends 17 Jun 2015

Deinove to challenge the Carotenoid Business

Carotenoids are powerfull antioxidants and essential in the production of vitamin A. The French synthetic biology biotech Deinove signed an agreement with the Canadian company POS Bio-Sciences with the hope of initiating a major breakthrough to the carotenoid market. Produced by all green plants, algae, some fungi and cyanobacteria, carotenoid is a group of more than 600 known […]

June 17, 2015 - 3 minutesmins - By Joachim Eeckhout

eye Bayer Healthcare Johns Hopkins University

News and Trends 16 Jun 2015

Bayer set a strategic alliance with J. Hopkins in retinal diseases

Bayer HealthCare and the Johns Hopkins University in Baltimore have entered into a five-year collaboration to develop ophthalmic therapies. The partners will jointly work on the discovery of treatments of retinal diseases such as age-related macular degeneration. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory […]

June 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Jun 2015

Novartis Uses Antibodies from Cured Patients to Fight Viruses

Novartis just paid the bill to Humabs to use its out-licensed drug candidate in a Phase II clinical trial. This monoclonal antibody was developed thanks to Humabs’ technology platform using antibodies from cured patients. Back in 2009, Humabs and Novartis entered into an exclusive licensing agreement for the use of selective human monoclonal antibodies discovered by […]

June 16, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 15 Jun 2015

GSK’s undercover incubator baked three new Biotechs

The partnership between GlaxoSmithKline and Avalon Ventures launched three early-stage life science companies. Adrenergics, CadheRx Therapeutics and Calporta Therapeutics will each receive up to €8.9M in a Series A financing, aside from support from their two godfathers. Three new companies were launched today as a result of Avalon’s fruitful collaboration with GSK. The partnership, which […]

June 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jun 2015

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

Genmab and its partner Jonhson&Jonhson, through its subsidiary Janssen Biotech, are trying to speed up daratumumab. The companies initiated a rolling submission for the candidate that targets multiple myeloma. The German-American partnership is trying to accelerate the arrival of daratumumab to the market, only just after the presentation of optimistic results of MOR202’s phase I/IIa. […]

June 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Jun 2015

The first-in-human proof that Epigenetics marks are transmitted to the offspring

If a father works out every night and day at the gym, will he have a brawny baby? Well, yes and no. It might sound Lamarckian but the French naturalist might have had a point. A team of researchers from the University of Cambridge has described for the first time in humans how some regions […]

June 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Jun 2015

MRC Technology and Peptinnovate partnered to cure bone diseases

MRC Technology and Peptinnovate teamed up to target bone diseases using peptides derived from the bacterium Mycobacterium tuberculosis. The partnership was created at Stevenage Bioscience Catalyst, a UK-based life sciences cluster. Natural peptides from M. tuberculosis, the pathogen that causes this feared disease, are able to modify the immunological and inflammatory response in humans. The bacteria employ […]

June 12, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 12 Jun 2015

Polaris, a new Nordic leader in Immuno-Oncology

Immuno-oncology is a busy market to take on by yourself due to the existing fierce competition. Targovax and Oncos Therapeutics have decided to merge to earn a spot in the field. Polaris, the combined business, contemplates a private placement of around €15M to fund the freshly baked company. Finland and Norway never were this close as Oncos […]

June 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Jun 2015

Cosmo’s dermatology spin-out Cassiopea IPOes before the end of its Phase III

Cassiopea, Cosmo Pharmaceutical’s spin-out, will be listed on the Swiss Stock Exchange. Cosmo Pharmaceutical plans to reduce its current 97% shareholding to below the 50% bar. The majority shareholder will give away the control of its subsidiary in order to have enough cash after the end of its Phase III ACNE-treatment, currently running in the US and […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Jun 2015

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

Pieris Pharmaceutical is planning to raise €31M in an surprisingly low US IPO. The company seeks to advance its early-stage pipeline with a special focus on its anemia treatment, Pieris’s most advanced candidate which recently completed the enrollment of its Phase I. Pieris’ pipeline might be premature, but it is ambitious. The company’s focus includes […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

diabetes type 2 sanofi novo nordisk eli lilly

News and Trends 11 Jun 2015

Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes

Hundreds of millions of people all over the word suffer from type 2 Diabetes and the competition between pharma companies is fierce. Amongst them, Sanofi must think that good things come to those who wait. After years of delay, the French colossus is convinced with the Phase IIIb results on its type 2 diabetes treatment. […]

June 11, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 10 Jun 2015

French collaboration to develop Oncology-targeted Therapy

PEP-Therapy and CleveXel Pharma will co-develop targeted therapy in oncology. The product is based on an innovative technology involving bi-functional peptides that penetrate cells, and specifically block pathological mechanisms without affecting physiological mechanisms. The drug candidate is a cell-penetrating peptide that targets an interaction between two intracellular proteins, Caspase-9 and PP2A. It has been validated […]

June 10, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Deinove to challenge the Carotenoid Business

Bayer set a strategic alliance with J. Hopkins in retinal diseases

Novartis Uses Antibodies from Cured Patients to Fight Viruses

GSK’s undercover incubator baked three new Biotechs

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

The first-in-human proof that Epigenetics marks are transmitted to the offspring

MRC Technology and Peptinnovate partnered to cure bone diseases

Polaris, a new Nordic leader in Immuno-Oncology

Cosmo’s dermatology spin-out Cassiopea IPOes before the end of its Phase III

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes

French collaboration to develop Oncology-targeted Therapy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!